In 2014, research by the AARP estimated that 40 million Americans provide unpaid care to an adult. About 68 percent of family caregivers have no paid help and by 2020, 45 million family caregivers will care for 117 million people, according to a new report on caregivers that is part of AARP’s Project Catalyst.
Food allergy has been referred to as the second wave of the allergy epidemic, asthma being the first.
The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
Chinese bidders are circling a diabetes care business owned by the world's largest health-care company Johnson & Johnson in a deal that could fetch up to $4 billion, five people with direct knowledge told Reuters.
Stimwave has raised $50 million to support commercialization of its neuromodulation pain therapies. The financing equips Stimwave to push ahead with its previously disclosed plans to make its devices available across the U.S.
Health IT funding set a record in 2017 with AI and predictive analytics as top tech funded, with patient engagement, telehealth and clinical decision support close behind.
Sick babies in remote parts of the world could be monitored from afar, thanks to new wearable technology designed by physicists at the University of Sussex.
Smiths Medical has amended an urgent medical device recall that it first issued in August for its Medfusion syringe pump model series 3500 and 4000.
TAI Diagnostics, Inc., focused on developing innovative diagnostic tests for monitoring the health of transplanted organs, announced the final closing of a $10 million Series A preferred equity financing. The company has now raised over $21 million since its inception. The proceeds of this financing will support on-going research and development of TAI’s innovative cell-free DNA (cfDNA) transplant monitoring technology, clinical studies, and the upcoming commercial launch of its post-transplant monitoring assays performed by its CLIA and CAP accredited reference laboratory.
Pfizer has collaborated with Foundation Medicine for the development of companion diagnostics (CDx) for its oncology portfolio.
Go to Page Go
your submission has already been received.
OK
Please enter a valid Email address!
Submit
The most relevant industry news & insight will be sent to you every two weeks.